{
    "nct_id": "NCT04693637",
    "official_title": "Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 1 Year",
    "exclusion_criteria": "* History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization\n* Evidence of active Grade >2 acute GVHD\n* Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections\n* Known history or current (suspected) diagnosis of CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies\n* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >0.5 mg/kg/day) within 24 hours prior to dosing\n* Relapse of primary malignancy other than minimal residual disease\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key Inclusion Criteria\n\n* â‰¥1 year of age at the day of screening visit.\n* Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening\n* Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment\n* Meet one or more of the following criteria at the time of randomization:\n\n  * Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR\n  * Haploidentical donor\n  * Unrelated donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B, -C, or -DR\n  * Use of umbilical cord blood as stem cell source\n  * Ex vivo graft manipulation resulting in T cell depletion\n  * Lymphocyte Count <180/mm3 and/or cluster of differentiation 4 (CD4) Count <50/mm3\n\nKey"
}